Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer News-Medical.net The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of ... |
